Article
Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC.
Cancer research - 1 Sept 2014
Tchaicha Jeremy H, Akbay Esra A, Altabef Abigail, Mikse Oliver R, Kikuchi Eiki, Rhee Kevin, Liao Rachel G, Bronson Roderick T, Sholl Lynette M, Meyerson Matthew, Hammerman Peter S, Wong Kwok-Kin
Abstract excerpt
Somatic mutations in FGFR2 are present in 4% to 5% of patients diagnosed with non-small cell lung cancer (NSCLC). Amplification and mutations in FGFR genes have been identified in patients with NSCLCs, and clinical trials are testing the efficacy of anti-FGFR therapies. FGFR2 and other FGFR kinase family gene alterations have been found in both lung squamous cell carcinoma and lung adenocarcinoma, although mouse...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.